Human papilloma virus genome is rare in North American non-small cell lung carcinoma patients

Yanagawa, Naoki; Wang, Ami; Kohler, Derek M.; Santos, Gilda da Cunha; Sykes, Jenna; Xu, Jing; Pintilie, Melania; Tsao, Ming‐Sound

doi:10.1016/j.lungcan.2012.11.018

Cited by 34 publications

(29 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Interestingly, Yanagawa et al [11] originally detected hrHPV in 5 SqCCs (of 336 surgically resected NSCLCs) using PCR and ISH for HPV DNA, and IHC for p16 and RB. They reported a 100% concordance rate between ISH and PCR.…”

Section: Discussionmentioning

confidence: 99%

“…RT-PCR to detect HPV mRNA is only used in occasional studies such as by van Boerdonk et al [10] and Coissard et al [19]. Drawing from studies with extremely low to absent detection rate for HPV in ADC and SqCC arising in lungs, most concluded that HPV-positive cases almost invariably have clinical suspicion for a metastatic process [10,11,15]. A detailed retrospective review of the medical record often revealed a history of SqCC from sites with established association with HPV infection, such as the oropharynx and cervix.…”

Section: Discussionmentioning

confidence: 99%

“…These authors concluded that IHC for p16 is not a surrogate marker for the presence of HPV and that HPV does not appear to be the cause of p16 overexpression in NSCLCs. This seems to suggest that the mechanism for p16 overexpression is achieved from a different pathway than through the inactivation of RB by HPV E7 oncoprotein [11]. More studies are needed to elucidate this phenomenon.…”

Section: Discussionmentioning

confidence: 99%

“…Sunnybrook Health Sciences Centre, 2075 range of HPV infection detected in lung ADC occurring in Asian populations varies from 0 to around 40% [7][8][9]. In contrast, several studies based on North American and European populations did not find an association between HPV infection and NSCLC [10][11][12][13]. A recent comprehensive meta-analysis [6] and an international pooled analysis [14] found that the variation in HPV detection rate may be a function of the geographical origin and histologic subtypes, rather than detection methods.…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Detection of human papillomavirus in non–small cell carcinoma of the lung

et al. 2015

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Detection of human papillomavirus in non–small cell carcinoma of the lung

et al. 2015

View full text Add to dashboard Cite

“…Tumors positive for the viruses are staged according to the schema for oropharynx and nasopharynx, respectively. For lymph node metastases that are keratinizing SCC or are located outside of the jugular chain, if the p16 comes back diffusely positive, then HPV-specific testing must be performed as a specificity check given the increased rates of nonspecific p16 positivity in other settings, particularly in skin [20] and lung SCC [21].…”

Section: Metastatic Squamous Cell Carcinoma Of Unknown Primarymentioning

confidence: 99%

Update from the 4th Edition of the World Health Organization Classification of Head and Neck Tumours: What Is New in the 2017 WHO Blue Book for Tumors and Tumor-Like Lesions of the Neck and Lymph Nodes

Katabi

Lewis

2017

Head and Neck Pathol

View full text Add to dashboard Cite

show abstract

The discordant biomarker dilemma: What are the diagnostic implications of oropharyngeal squamous cell carcinomas with discrepant p16 and HPV results?

Guzmán-Arocho

Nishino

2022

Cancer Cytopathology

View full text Add to dashboard Cite

High-risk human papillomavirus (HPV)-associated oropharyngeal squamous cell carcinoma (OPSCC) exhibits distinctive clinical, pathologic, epidemiologic, and prognostic features. 1 Because of the better treatment response and survival profiles associated with HPV-associated versus HPV-independent OPSCC, the American Joint Committee on Cancer and Union for International Cancer Control staging systems currently risk stratify OPSCC differently, depending on high-risk HPV (HR-HPV) status. [2][3][4][5][6][7] Selected patients with HPV-mediated OPSCC may be eligible for clinical trials investigating less intensive treatment regimens relative to standardof-care surgery, radiotherapy, and/or chemotherapy protocols. 8-10 Therefore, HR-HPV status should be determined on the primary tumor or regional lymph node metastasis of all newly diagnosed OPSCC. 11 Different methodologies for HR-HPV-specific testing are available, including DNA-based polymerase chain reaction (PCR), 12,13 DNA-based in situ hybridization (ISH), 7,14,15 RNA-based quantitative reverse transcriptase-PCR, 16,17 and E6/E7 messenger RNA detection by ISH. 18,19 Immunohistochemistry (IHC) for p16 has emerged as a surrogate marker for HR-HPV in the oropharynx because it is widely available, shows excellent interobserver agreement, demonstrates reliable performance on small specimens, and is relatively affordable compared with HPV-specific molecular testing. 20,21 For histologic specimens of OPSCC, the College of American Pathologists (CAP) recommends p16 IHC as the primary testing modality for HPV status, with moderate-to-strong nuclear and cytoplasmic p16 staining in ≥70% of tumor cells considered a sensitive and reasonably specific threshold for transcriptionally active HR-HPV. 11,22 The recommendation for p16 and/or HR-HPV-specific testing also applies to fine-needle aspiration (FNA) biopsies of upper-jugular to mid-jugular (level II-III) neck lymph nodes with metastatic squamous cell carcinoma. Although CAP guidelines do not advise for or against any particular HPV testing method for FNA cytology samples, numerous studies have highlighted the lower sensitivity of p16 immunostaining for HR-HPV when interpretive criteria established for histology samples are applied to alcohol-fixed cell block material. [23][24][25][26][27][28][29] Accordingly, we routinely apply lower interpretive thresholds for p16 immunostaining and/or bypass p16 IHC altogether in favor of HR-HPVspecific testing for FNA cell block specimens prepared from CytoLyt. For patients with negative p16 and/or HR-HPV-specific testing results on FNA cytology material, repeat testing on subsequent histology specimens is recommended if a surgical or tissue biopsy sample becomes available. 11 Notably, the lower sensitivity of p16 staining in cell blocks has not been observed for aspirates collected directly into formalin, underscoring the importance of fixative and other preanalytic factors in interpreting this immunostain. 23 Although studies from the United Kingdom have recommended routine HR-HPV-specif...

show abstract

Human papilloma virus genome is rare in North American non-small cell lung carcinoma patients

Cited by 34 publications

References 22 publications

Detection of human papillomavirus in non–small cell carcinoma of the lung

Detection of human papillomavirus in non–small cell carcinoma of the lung

Update from the 4th Edition of the World Health Organization Classification of Head and Neck Tumours: What Is New in the 2017 WHO Blue Book for Tumors and Tumor-Like Lesions of the Neck and Lymph Nodes

The discordant biomarker dilemma: What are the diagnostic implications of oropharyngeal squamous cell carcinomas with discrepant p16 and HPV results?

Contact Info

Product

Resources

About